Stephen Hanauer to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Stephen Hanauer has written about Randomized Controlled Trials as Topic.
Connection Strength
1.200
-
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723.
Score: 0.108
-
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
Score: 0.107
-
Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.
Score: 0.106
-
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf. 2015; 14(12):1915-34.
Score: 0.101
-
Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):1981-90.
Score: 0.094
-
Treat the patient or treat the disease? Dig Dis. 2012; 30(4):400-3.
Score: 0.080
-
Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010 Dec 08; (12):CD008870.
Score: 0.072
-
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
Score: 0.065
-
Fertile ground. Nat Clin Pract Gastroenterol Hepatol. 2006 Oct; 3(10):533.
Score: 0.054
-
Treatment of Crohn's disease: the "long" of it. Gastroenterology. 2005 Jun; 128(7):2164-6.
Score: 0.049
-
Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 May; 2(5):379-88.
Score: 0.046
-
Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85.
Score: 0.045
-
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24.
Score: 0.045
-
The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
Score: 0.042
-
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
Score: 0.040
-
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281.
Score: 0.035
-
Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut. 1999 Apr; 44(4):455.
Score: 0.032
-
Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9.
Score: 0.019
-
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56.
Score: 0.019
-
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
Score: 0.018
-
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660.
Score: 0.018
-
Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials. Dig Dis Sci. 1990 Jul; 35(7):827-32.
Score: 0.004